Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 19/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17821487 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL17821503 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL17821486 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL16405622 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL16405372 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL17821509 | 0.95 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL17821492 | 0.95 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL17821495 | 0.95 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL16399220 | 0.95 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL16403391 | 0.95 | EGFR (1.00) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022186-B1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2020-02-26 | — | — | EP | claimed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | claimed |
| CN-107892684-B | Quinazoline derivatives, pharmaceutical compositions thereof, and use as medicaments | 锦州奥鸿药业有限责任公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3022186-B1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2020-02-26 | — | — | EP | disclosed |
| EP-3022186-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | EGFR 2069/4885ERBB2 489/4885ERBB4 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.